HUS1500053I1 - Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal - Google Patents

Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal

Info

Publication number
HUS1500053I1
HUS1500053I1 HUS1500053C HUS1500053C HUS1500053I1 HU S1500053 I1 HUS1500053 I1 HU S1500053I1 HU S1500053 C HUS1500053 C HU S1500053C HU S1500053 C HUS1500053 C HU S1500053C HU S1500053 I1 HUS1500053 I1 HU S1500053I1
Authority
HU
Hungary
Prior art keywords
nnrtis
pyrimidine
inhibitors
combinations
containing nnrtis
Prior art date
Application number
HUS1500053C
Other languages
English (en)
Hungarian (hu)
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1500053(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of HUS1500053I1 publication Critical patent/HUS1500053I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUS1500053C 2003-09-03 2015-10-21 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal HUS1500053I1 (hu)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
EP04787096.9A EP1663240B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (1)

Publication Number Publication Date
HUS1500053I1 true HUS1500053I1 (hu) 2016-03-29

Family

ID=34280181

Family Applications (5)

Application Number Title Priority Date Filing Date
HUS1500054C HUS1500054I1 (hu) 2003-09-03 2015-10-21 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1500053C HUS1500053I1 (hu) 2003-09-03 2015-10-21 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1500052C HUS1500052I1 (hu) 2003-09-03 2015-10-21 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1600059C HUS1600059I1 (hu) 2003-09-03 2016-12-20 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1600058C HUS1600058I1 (hu) 2003-09-03 2016-12-20 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUS1500054C HUS1500054I1 (hu) 2003-09-03 2015-10-21 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUS1500052C HUS1500052I1 (hu) 2003-09-03 2015-10-21 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1600059C HUS1600059I1 (hu) 2003-09-03 2016-12-20 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1600058C HUS1600058I1 (hu) 2003-09-03 2016-12-20 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal

Country Status (24)

Country Link
US (9) US20080200435A1 (enExample)
EP (1) EP1663240B2 (enExample)
JP (3) JP5507791B2 (enExample)
KR (1) KR20060090658A (enExample)
CN (1) CN101060844B (enExample)
AP (1) AP2109A (enExample)
AU (5) AU2004268390B2 (enExample)
BE (1) BE2015C053I2 (enExample)
CA (1) CA2537095C (enExample)
CY (5) CY2015038I2 (enExample)
FI (1) FI1663240T4 (enExample)
FR (5) FR15C0071I2 (enExample)
HR (1) HRP20150798T4 (enExample)
HU (5) HUS1500054I1 (enExample)
IL (2) IL173438A (enExample)
LT (2) LTPA2016045I1 (enExample)
LU (3) LU92853I2 (enExample)
MX (1) MXPA06002437A (enExample)
MY (1) MY169670A (enExample)
NL (2) NL300781I1 (enExample)
NO (6) NO334877B1 (enExample)
NZ (1) NZ545306A (enExample)
PL (1) PL1663240T5 (enExample)
WO (1) WO2005021001A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
CN101481356B (zh) 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1632232B3 (en) * 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
EA011036B1 (ru) * 2004-09-02 2008-12-30 Янссен Фармацевтика Н.В. Фумарат 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
CN101056673A (zh) * 2004-09-02 2007-10-17 詹森药业有限公司 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
KR101284361B1 (ko) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2633603C (en) * 2005-12-14 2016-09-13 Cipla Limited Pharmaceutical combination
USRE50189E1 (en) * 2006-01-20 2024-10-29 Janssen Sciences Ireland Unlimited Company Long term treatment of HIV-infection with TMC278
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
ES2573641T3 (es) * 2008-01-03 2016-06-09 Université D'aix-Marseille Triterapia utilizable para el tratamiento de un paciente infectado por VIH
AU2009332910B2 (en) * 2008-12-24 2015-10-15 Janssen Sciences Ireland Uc Implantable devices for treating HIV
WO2011080141A2 (en) 2009-12-21 2011-07-07 Tibotec Pharmaceuticals Degradable removable implant for the sustained release of an active compound
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
EA025852B1 (ru) 2010-11-19 2017-02-28 Джилид Сайэнс, Инк. ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ РИЛПИВИРИН HCl И ТЕНОФОВИРА ДИЗОПРОКСИЛФУМАРАТ
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
CA2848631C (en) * 2011-09-16 2019-10-01 Hetero Research Foundation Rilpivirine hydrochloride
SI3067358T1 (sl) 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
CN108348473B (zh) 2015-11-09 2021-06-18 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
CA3039562A1 (en) 2016-10-24 2018-05-03 Janssen Sciences Ireland Unlimited Company Dispersible compositions
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
US11234981B2 (en) 2017-04-18 2022-02-01 Cipla Limited Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
JPH07112975B2 (ja) 1990-07-19 1995-12-06 大塚製薬株式会社 固型製剤
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
EP0639971B1 (en) 1992-05-13 1999-09-22 The Wellcome Foundation Limited Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IL148685A0 (en) 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
KR20030011805A (ko) 2000-03-30 2003-02-11 브리스톨-마이어스스퀴브컴파니 스타부딘을 함유하는 서방성 비들렛
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
US20040058956A1 (en) 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
JP2005511629A (ja) 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
CN101481356B (zh) 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
AU2003291457A1 (en) 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
NZ540321A (en) 2002-11-15 2007-09-28 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AR049297A1 (es) 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
EP1632232B3 (en) 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
AU2006235565A1 (en) * 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
JP2009502969A (ja) 2005-07-28 2009-01-29 アイエスピー インヴェストメンツ インコーポレイテッド 非晶質エファビレンツ及びその製造
USRE50189E1 (en) 2006-01-20 2024-10-29 Janssen Sciences Ireland Unlimited Company Long term treatment of HIV-infection with TMC278
AP2618A (en) 2006-06-23 2013-03-18 Tibotec Pharmaceutical Ltd Aqueous suspensions of TMC278
WO2008060360A2 (en) * 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
SI2175857T1 (sl) 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
EP2358198A4 (en) * 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

Also Published As

Publication number Publication date
AU2016210733A1 (en) 2016-08-25
HRP20150798T4 (hr) 2023-06-09
HUS1600059I1 (hu) 2017-02-28
FR15C0071I2 (fr) 2016-02-12
IL213104A (en) 2016-02-29
CN101060844A (zh) 2007-10-24
AU2019200813A1 (en) 2019-02-28
LTPA2016044I1 (lt) 2017-01-10
CY2015040I1 (el) 2016-08-31
LU92853I2 (fr) 2015-12-21
FR15C0071I1 (enExample) 2015-04-12
CY2015038I1 (el) 2016-08-31
US20150283135A1 (en) 2015-10-08
AU2004268390A1 (en) 2005-03-10
NL300781I2 (enExample) 2016-04-19
US20080200435A1 (en) 2008-08-21
NL300781I1 (enExample) 2016-04-19
AU2011201123B2 (en) 2013-10-10
FI1663240T4 (fi) 2023-04-25
HRP20150798T1 (hr) 2015-09-11
NZ545306A (en) 2009-11-27
NO2014030I2 (no) 2014-12-18
KR20060090658A (ko) 2006-08-14
MY169670A (en) 2019-05-08
FR15C0073I1 (enExample) 2015-04-12
CY2015039I2 (el) 2016-08-31
CY2016049I2 (el) 2017-07-12
NO2014031I1 (no) 2015-01-05
US20200171027A1 (en) 2020-06-04
FR15C0072I1 (enExample) 2015-04-12
NO334877B1 (no) 2014-06-23
AP2006003551A0 (en) 2006-04-30
FR16C1024I1 (fr) 2017-02-03
EP1663240B1 (en) 2015-04-22
CY2016049I1 (el) 2017-07-12
LU92854I2 (fr) 2015-12-21
PL1663240T5 (pl) 2024-02-26
JP2007520443A (ja) 2007-07-26
US20180228800A1 (en) 2018-08-16
NO2014032I2 (no) 2014-12-18
WO2005021001A1 (en) 2005-03-10
HUS1600058I1 (hu) 2017-02-28
NO2016025I1 (enExample) 2016-12-20
US20140349971A1 (en) 2014-11-27
AU2011201123A1 (en) 2011-04-07
NL300768I1 (enExample) 2015-12-16
MXPA06002437A (es) 2006-06-20
JP5507791B2 (ja) 2014-05-28
AU2014203484A1 (en) 2014-07-17
NO2014030I1 (no) 2015-01-05
US8841310B2 (en) 2014-09-23
NO2014031I2 (no) 2014-12-18
JP2012051915A (ja) 2012-03-15
CY2015039I1 (el) 2016-08-31
EP1663240A1 (en) 2006-06-07
CA2537095C (en) 2012-05-29
HUS1500052I1 (hu) 2016-03-29
JP2015044839A (ja) 2015-03-12
IL213104A0 (en) 2011-07-31
US20220008417A1 (en) 2022-01-13
AU2016210733B2 (en) 2018-11-08
CA2537095A1 (en) 2005-03-10
FR15C0072I2 (fr) 2019-05-17
LTPA2016045I1 (lt) 2017-01-10
HUS1500054I1 (hu) 2016-03-29
CY2016048I2 (el) 2017-07-12
FR15C0073I2 (fr) 2016-02-12
LTC1663240I2 (lt) 2022-05-25
CY2016048I1 (el) 2017-07-12
NL300768I2 (nl) 2023-08-09
LU92855I2 (fr) 2015-12-21
PL1663240T3 (pl) 2015-10-30
CN101060844B (zh) 2012-01-04
HK1092698A1 (en) 2007-02-16
IL173438A (en) 2012-03-29
US20100029591A1 (en) 2010-02-04
BE2015C053I2 (enExample) 2023-12-14
CY2015038I2 (el) 2016-08-31
EP1663240B2 (en) 2023-03-01
NO2014032I1 (no) 2015-01-05
US20170100398A1 (en) 2017-04-13
CY2015040I2 (el) 2016-08-31
AU2014203484B2 (en) 2016-09-29
FR16C1022I1 (fr) 2017-02-03
JP5820045B2 (ja) 2015-11-24
NO20061374L (no) 2006-03-27
IL173438A0 (en) 2006-06-11
AU2004268390B2 (en) 2011-03-31
NO2016026I1 (no) 2016-12-20
AP2109A (en) 2010-02-26
US20190216807A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
HUS1600058I1 (hu) Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1730146T3 (da) Azaindoler anvendelige som inhibitorer af JAK og andre proteinkinaser
DK1664043T3 (da) Sammensætninger egnede som inhibitorer af proteinkinaser
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK1611112T3 (da) Isoxazolforbindelser som hæmmere af varmechokproteiner
NO20045220L (no) Heterocykliske inhibitorer for kinaser
DK1532145T3 (da) Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3
ATE370124T1 (de) Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase
CY2013046I2 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
DE602005027308D1 (de) Stabile salze von olanzapin
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
EP1697331A4 (en) INHIBITORS OF MITOTIC KINESINE
ZA200700751B (en) Azalndoles useful as inhibitors of protein kinases
EP1697381A4 (en) INHIBITORS OF MITOTIC KINESINE
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
TWI365744B (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1954717A4 (en) PEPTIDE INHIBITORS OF ABL KINASE
DE112005000126D2 (de) Verwendungen von Glaskeramiken